23andMe, founded in April 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. The company has not officially endorsed a plan to participate in an IPO.

23andMe provides at-home, consumer genetic testing and was the first FDA-approved direct-to-consumer genetic sequencing supplier. More recently, 23andMe has leveraged its genetic database in pursuit of pharmaceutical drug development. The company has raised nearly $800 million in Venture Capital funding from investors including GlaxoSmithKline, Pegasus Tech Ventures, MicroVentures, G Squared, Sapphire Ventures, Sequoia Capital, SharesPost, Fidelity, GV, and Genetech. It has been widely reported that 23andMe last raised $300 million in July 2018 at a post-money valuation of $2.5 billion.

Register for Details

For more details on financing and valuation for 23andMe, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is 23andMe's ticker symbol?


What is 23andMe's stock price?

1.08 as of 9/25/23

Who are 23andMe's major investors?

Fidelity Investments
Casdin Capital
Altimeter Capital

23andMe Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
12/23/2020 Series F-1 $385MM raised $XXX.XX $XXX.XX
9/12/2017 Series F $250MM raised $XXX.XX $XXX.XX
6/8/2015 Series E $115.25MM raised $XXX.XX $XXX.XX
12/10/2012 Series D $58.45MM raised $XXX.XX $XXX.XX
11/10/2010 Series C $31.18MM raised $XXX.XX $XXX.XX
12/23/2009 Series B $27.78MM raised $XXX.XX $XXX.XX
5/22/2007 Series A $8.95MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about 23andMe

Forge green plus iconForge green minus icon

What is 23andMe funding to date?

23andMe has raised $876.61MM to date.
Forge green plus iconForge green minus icon

When was 23andMe founded?

23andMe was founded in 2006.
Updated on: Sep 1, 2022